Olmesartan Medoxomil and Hydrochlorothiazide Tablets
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20223891
Indications:
This product is suitable for the treatment of hypertension. Indicated in patients whose blood pressure is not adequately controlled with olmesartan medoxomil or hydrochlorothiazide alone. This product is a fixed-dose compound preparation and is not suitable for the initial treatment of hypertension.
This product can be used alone or in combination with other antihypertensive drugs.
Control of hypertension is part of the comprehensive management of cardiovascular risk, which may include lipid control, diabetes management, antithrombotic therapy, smoking cessation, physical activity, and sodium restriction.
Elevated systolic or diastolic blood pressure increases cardiovascular risk. At higher basal blood pressure levels, the absolute risk of an increase in blood pressure per millimeter of Hg is higher. The relative magnitude of the risk reduction in blood pressure reduction was similar in people with different absolute cardiovascular risks. In patients with severe hypertension, a slight reduction in blood pressure can bring greater clinical benefit.
In adults with hypertension, lowering blood pressure generally reduces the risk of cardiovascular events, primarily stroke and myocardial infarction.
However, there is no evidence of controlled clinical trials for this product to reduce cardiovascular risk.
Administration:
Olmesartan medoxomil is usually recommended as a monotherapy drug in euvolemic patients, with a starting dose of 20 mg once daily. For patients who require further lowering of blood pressure after 2 weeks of treatment, the dose can be increased to 40 mg. Doses greater than 40 mg did not show a greater antihypertensive effect. Twice-daily dosing did not show superiority over once-daily dosing at the same dosage.
There is no need to adjust the starting dose in older patients, patients with moderate to significant renal impairment (creatinine clearance < 40 mL/minute), or patients with moderate to significant hepatic impairment. Patients with probable volume depletion (e.g., patients receiving diuretic therapy, especially those with renal impairment) must be started under close medical supervision, and a lower starting dose may be considered. The effective dosage of hydrochlorothiazide is 12.5 mg to 50 mg once daily.
Combination therapy is usually started after a satisfactory response to one-component therapy with olmesartan medoxomil or hydrochlorothiazide has not been obtained.
This product is taken orally, 1 time daily, 1 tablet each time. This product can be taken regardless of whether patients have eaten or not.
The dosage of this product should be individualized. Based on the antihypertensive effect, the dose can be adjusted at intervals of 2~4 weeks. In the dose range of 10mg/12.5mg to 40mg/25mg, the antihypertensive effect of this product is correlated with the dose administered.
The antihypertensive effect of olmesartan medoxomil and hydrochlorothiazide tablets begins within one week and reaches the maximum antihypertensive effect at four weeks.
This product can be used in combination with other antihypertensive drugs.
If the patient's creatinine clearance rate > 30mL/min, the conventional dose of this product can be used. In patients with more severe renal impairment, loop diuretics will be superior to thiazide diuretics, so this product is not recommended.
Patients with hepatic impairment do not need to adjust the dose.
Specification:
20mg/12.5mg × 14 tablets
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.